Literature DB >> 1613446

What is a normal stimulated growth hormone concentration?

M T Dattani1, P J Pringle, P C Hindmarsh, C G Brook.   

Abstract

In a retrospective analysis, we have compared the response of serum GH concentration to insulin-induced hypoglycaemia in 148 short prepubertal children (114 males, 34 females) aged between 3.9 and 11.9 years with the growth rate of the individual to determine 'cut-off' values for the diagnosis of GH insufficiency. Sixty-three children grew with a height velocity standard deviation score (SDS) greater than -0.8 (group 1), which represents the growth velocity of children progressing along or closely parallel to the third height centile. Eighty-five children had a height velocity SDS of less than -0.8 (group 2). Median peak serum GH concentration responses to insulin-induced hypoglycaemia were 19.9 mU/l (range 1.5-54.4) in group 1 and 9.9 mU/l (range 0.7-46.2) in group 2 (Mann-Whitney; P less than 0.001). Using growth rate as the determinant of normality, the efficiency, sensitivity and specificity of the insulin-induced hypoglycaemia test were calculated using different serum GH concentration cut-off values to diagnose GH insufficiency. In our (Hybritech) assay, a cut-off value of 13.5 mU/l provided optimal performance in terms of efficiency (66%), sensitivity (64%) and specificity (70%). The response of serum GH concentration to insulin-induced hypoglycaemia in short children growing at different growth rates was continuous. Each laboratory measuring serum GH concentrations needs to construct its own 'normal' cut-off value.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613446     DOI: 10.1677/joe.0.1330447

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

1.  Which children should receive growth hormone treatment. Cost-benefit analysis is the key.

Authors:  C J Kelnar
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

2.  Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency.

Authors:  H Mitchell; M T Dattani; V Nanduri; P C Hindmarsh; M A Preece; C G Brook
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

Review 3.  An assessment of growth hormone provocation tests.

Authors:  P C Hindmarsh; P G Swift
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

4.  Transsphenoidal surgery for pituitary tumours.

Authors:  A F Massoud; M Powell; R A Williams; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1997-05       Impact factor: 3.791

5.  Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA).

Authors:  A Ciresi; F Cicciò; M C Amato; C Giordano
Journal:  J Endocrinol Invest       Date:  2015-05-27       Impact factor: 4.256

6.  Unreliability of classic provocative tests for the diagnosis of growth hormone deficiency.

Authors:  A Mazzola; C Meazza; P Travaglino; S Pagani; D Frattini; E Bozzola; G Corneli; G Aimaretti; M Bozzola
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

7.  Growth hormone response to oral clonidine test in normal and short children.

Authors:  S Loche; M Cappa; E Ghigo; A Faedda; A Lampis; D Carta; C Pintor
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

8.  Current practice in diagnosis and treatment of growth hormone deficiency in childhood: a survey from Turkey.

Authors:  Şükran Poyrazoğlu; Teoman Akçay; İlknur Arslanoğlu; Mehmet Emre Atabek; Zeynep Atay; Merih Berberoğlu; Abdullah Bereket; Aysun Bideci; İffet Bircan; Ece Böber; Şule Can; Yaşar Cesur; Şükran Darcan; Korcan Demir; Bumin Dündar; Betül Ersoy; İhsan Esen; Ayla Güven; Cengiz Kara; Mehmet Keskin; Selim Kurtoğlu; Nihal Memioğlu; Mehmet Nuri Özbek; Tolga Özgen; Erkan Sarı; Zeynep Şıklar; Enver Şimşek; Serap Turan; Ediz Yeşilkaya; Bilgin Yüksel; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.